Three independent discounted-cash-flow-style models value West Pharmaceutical Services, Inc. every trading day. 0 of 3 currently price WST above its market price.
| Free Cash Flow model | $54.02 |
| Excess Profit model | $81.82 |
| Residual Earnings model | $47.73 |
| Dividend Discount model | $14.12 |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +14.4% |
| Net debt / EBITDA | -0.6× |
| Gross margin | +35.9% |
| Revenue CAGR | +2.1% |
| Cash conversion | 1.5× |
| Dividend yield | +0.2% |
| Buyback yield | +0.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open WST in StockKitty